Do you have Relapsed and Refractory CLL, SLL, or Select Low-grade Lymphomas? Have you received at least 2 or more therapies that have included BTKi and venetoclax? If so, you may be able to take part in a study on a drug called ZE50-0134 to treat patients with these conditions. We will also check if various doses of this medicine are safe for treatment.

Have you been diagnosed with CLL or other forms of indolent lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of this study is To investigate the feasibility of the referral and engagement process in fatigue mitigation intervention for cancer-related fatigue among adults with CLL or other forms of indolent lymphoma.

We want to learn how couples dealing with prostate cancer handle food preparation and eating together.

Do you have multiple myeloma (MM)? Has your MM returned after responding to initial treatment (relapsed) or is not responding to treatment (refractory)? If so, you may be able to participate in this cell therapy research study to learn more about using modified immune cells as possible treatment.

Do you have metastatic colorectal cancer? Does your cancer lack certain mutations? If so, you might be eligible to take part in a trial to look at the effects of an investigational anticancer drug given with normal therapy.

If you have Polycythemia Vera and are experiencing complications, you may be eligible to participate in a research study testing the safety of a new drug called GIVinostat.

Do you have recurring Chronic Lymphocytic Leukemia? If so, you may be able to take part in a study on two medicines to treat patients whose chronic lymphocytic leukemia has come back. We will also check if this treatment is safe for treatment.

Do you have thyroid cancer? If so, you may be eligible to participate in a research study to see which targeted therapy will work better to prolong the time until your tumor grows or spreads, after initial treatment.

Have you been diagnosed with early-stage breast cancer or ductal carcinoma in situ (DCIS) and have undergone breast conserving surgery (lumpectomy). If so this may be the research for you!! You may be able to take part in a research study to evaluate the effects of the tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with the WBI, as opposed to after the WBI.

If you have a solid tumor that has not responded to other treatments and have no remaining therapy options, you may be eligible for the trial. Participants will receive the study drug at no cost.